bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

NCT06070636 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Liver Diseases
Hepatocellular Carcinoma
Immunotherapy
Lenvatinib
Sintilimab

Interventions

PROCEDURE: bTAE-HAIC
DRUG: Lenvatinib
DRUG: Sintilimab

Sponsor

Sun Yat-sen University